These people make no sense to me! They will do everything they can to ban e-cigs and yet here they are saying "yes we know that AVANDIA can cause heart attacks but we will keep it on the market. (And the little boy said hmmmmm)
FDA panel votes to keep Avandia on the market - Health - Diabetes - msnbc.com
FDA panel votes to keep Avandia on the market
Agency to make final decision on the diabetes drug in coming months
A majority of U.S. government health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack.
A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. Panelists who voted to keep the drug on the market were split between several options, including adding new warning labels and restricting use of the drug.
The Food and Drug Administration has convened the panel to help untangle reams of conflicting data over whether the GlaxoSmithKline drug increases heart risks.
Despite an earlier vote that Avandia increases heart risks, panelists said the evidence wasn't strong enough to remove it from the market.
The agency will make the final decision in the coming months but usually follows the advice of its advisory committees.
Avandia's U.S. sales were just 1.5 percent of Glaxo's 2009 revenues, but investors feared the company could face more lawsuits if the drug was forced from the market.
The advisory panel heard two days of sharply conflicting opinions from inside and outside the FDA, and reviewed hundreds of pages of data, before coming to its decision.
Newsvine poll: Should Avandia remain on the market?
The debate on Avandia's safety has raged since warnings were placed on the drug in 2007 saying some research linked the drug to a higher heart attack risk but the data was "inconclusive."
© 2010 msnbc.com
FDA panel votes to keep Avandia on the market - Health - Diabetes - msnbc.com
FDA panel votes to keep Avandia on the market
Agency to make final decision on the diabetes drug in coming months
A majority of U.S. government health experts has voted to keep the controversial diabetes pill Avandia on the market despite evidence that it increases the risk of heart attack.
A panel of Food and Drug Administration advisers voted 20-12 against withdrawing GlaxoSmithKline's once-blockbuster drug. Panelists who voted to keep the drug on the market were split between several options, including adding new warning labels and restricting use of the drug.
The Food and Drug Administration has convened the panel to help untangle reams of conflicting data over whether the GlaxoSmithKline drug increases heart risks.
Despite an earlier vote that Avandia increases heart risks, panelists said the evidence wasn't strong enough to remove it from the market.
The agency will make the final decision in the coming months but usually follows the advice of its advisory committees.
Avandia's U.S. sales were just 1.5 percent of Glaxo's 2009 revenues, but investors feared the company could face more lawsuits if the drug was forced from the market.
The advisory panel heard two days of sharply conflicting opinions from inside and outside the FDA, and reviewed hundreds of pages of data, before coming to its decision.
Newsvine poll: Should Avandia remain on the market?
The debate on Avandia's safety has raged since warnings were placed on the drug in 2007 saying some research linked the drug to a higher heart attack risk but the data was "inconclusive."
© 2010 msnbc.com
